

Supplementary Materials

Supplementary Table 1. Control definitions for each score. The definition of “controls” shown in Figure 3 is different for each score, where all diseases listed for each score were removed from the control pool, along with anyone who reported IBS or its subtypes. The count of comorbidities (n) is shown alongside the minimum size of the control pool (x) available for 1:5 matching, which was determined by subtracting the number of excluded cases (plus all IBS cases) from the size of the validation cohort ($n = 71,220$). For odds ratios based on Rome IV criteria, any positive IBS classification was also excluded from controls.

Score Name (n = comorbidity count; x = minimum control pool)	Comorbidities excluded from controls	References
<i>ButyrateProductionPathways</i> ($n = 37$; $x = 39,021$)	Acne, Atherosclerosis, Atopic dermatitis, <i>C. difficile</i> infection, Cardiovascular condition, Colon polyps, Colorectal cancer, Congestive heart failure, COPD, Coronary heart disease, Crohn's disease, Cystic acne, Depression, Dermatitis (Skin rashes or irritation), Dysglycemia / Irregular blood sugar, Eczema, Emphysema, GI inflammation, Gout, <i>H. pylori</i> infection, High lipids, Hypercholesterolemia, Hypertension, Inflammatory bowel disease, Insomnia, Leaky gut, Liver cirrhosis, Major depressive disorder, Osteoarthritis, Osteoporosis, Prediabetes, Psoriasis, Psoriatic arthritis, Rheumatoid arthritis, Type 1 diabetes, Type 2 diabetes, Ulcerative colitis	[Ex4-Ex30]
<i>GABAProductionPathways</i> ($n = 17$; $x = 46,045$)	Anxiety, Autism, Behavioral / Mood disorder, Colon polyps, Colorectal cancer, Crohn's disease, Depression, Dysmotility, Epilepsy, Inflammatory bowel disease, Irritable bowel syndrome-Diarrhea, Insomnia, Leaky gut, Metabolic syndrome, NAFLD, Type 1 diabetes, Type 2 diabetes, Ulcerative colitis	[Ex31-Ex43]
<i>LacticAcidProductionPathways</i> ($n = 16$; $x = 51,028$)	Chronic fatigue syndrome, Colon polyps, Colorectal cancer, Crohn's disease, Dysbiosis, Gastritis, Infections, Irritable bowel syndrome-Diarrhea, Inflammatory bowel disease, Insulin resistance, Ischemic colitis, Metabolic syndrome, Prediabetes, Short bowel syndrome, Type 2 diabetes, Ulcerative colitis	[Ex2,Ex44-Ex57]
<i>LPSBiosynthesisPathways</i> ($n = 39$; $x = 38,062$)	Alcohol addiction, Allergies, ALS, Alzheimer's disease, Anxiety, Atherosclerosis, Autism, Cardiovascular condition, Celiac disease, Cognitive dysfunction / Cognitive impairment, Colon polyps, Colorectal cancer, Coronary heart disease, Crohn's disease, Depression, Dysbiosis, GI inflammation, HIV, Inflammatory bowel disease, Influenza, Insulin resistance, Kidney disease, Leaky gut, Liver cirrhosis, Metabolic syndrome, Mild cognitive impairment, NAFLD, Obesity, Osteoarthritis, Pancreatic Cancer, Pancreatitis, Parkinson's disease, Peripheral artery disease, Prediabetes, Rheumatoid arthritis, Sepsis, SIBO, Type 2 diabetes, Ulcerative colitis	[Ex1,Ex58-Ex77]
<i>MethanogenesisPathways</i> ($n = 32$; $x = 44,552$)	Abdominal weight, Abnormal fasting glucose, Anorexia, Colon polyps, Colorectal cancer, Crohn's disease, Diverticulitis, Diverticulosis, Dysbiosis, Dysglycemia / Irregular blood sugar, Encopresis, Gastritis, Gastroparesis, GI inflammation, <i>H. pylori</i> , High lipids, Hypercholesterolemia, Infections, Irritable bowel syndrome-Constipation, Inflammatory bowel disease, Insulin resistance, Leaky gut, Metabolic syndrome, Multiple sclerosis, NAFLD, Obesity, Parkinson's disease, Prediabetes, SIBO, Type 1 diabetes, Type 2 diabetes, Ulcerative colitis	[Ex3,Ex78-Ex122]
<i>OxalateMetabolismPathways</i> ($n = 19$; $x = 43,222$)	Abdominal weight, Cardiovascular condition, Colon polyps, Colorectal cancer, Coronary heart disease, Crohn's disease, Hashimoto's disease, Hypertension, Hyperthyroidism, Hypothyroidism, Inflammatory bowel disease, Kidney disease, Kidney stones, Obesity, Short bowel disease, Stroke, Thyroid cancer, Thyroid nodule(s), Ulcerative colitis	[Ex123-Ex134]
<i>SulfideProductionPathways</i> ($n = 16$; $x = 53,736$)	Colon polyps, Colorectal cancer, Crohn's disease, Diverticulitis, Diverticulosis, GI inflammation, <i>H. pylori</i> infection, Infections, Inflammatory bowel disease, Irritable bowel syndrome-Constipation, Irritable bowel syndrome-Diarrhea, Irritable bowel syndrome, Leaky gut, Parkinson's disease, SIBO, Ulcerative colitis	[Ex135-Ex141]
<i>UricAcidProductionPathways</i> ($n = 14$; $x = 49,983$)	Colon polyps, Colorectal cancer, Crohn's disease, Gout, Hypertension, Inflammatory bowel disease, Insulin resistance, Kidney disease, Kidney stones, Metabolic syndrome, Obesity, Prediabetes, Type 2 diabetes, Ulcerative colitis	[Ex142-Ex151]


Supplementary Table 2. Odds Ratio and Confidence Intervals shown in Figure 3. IBS cases are the composite of IBS and all IBS subtypes while “control” definitions are score-specific (Supplementary Table 1). Values represent Odds Ratios. Significance levels of the p-values are shown in superscript, with 95% Confidence Interval in parentheses. $p \leq 0.05$ (*); $p \leq 0.01$ (**); $p \leq 0.001$ (**); not significant (ns).

Score Name	IBS (max $n = 6,373$)	IBS-C (max $n = 1,732$)	IBS-D (max $n = 1,006$)	IBS-M (max $n = 1,091$)
<i>ButyrateProductionPathways</i>	1.3*** (1.2 - 1.5)	0.8* (0.7 - 0.9)	2.6*** (2.1 - 3.3)	1.5*** (1.2 - 1.9)
<i>GABAProductionPathways</i>	1.7*** (1.5 - 1.8)	2.1*** (1.8 - 2.6)	1.6*** (1.3 - 2.0)	1.5*** (1.2 - 1.9)
<i>LacticAcidProductionPathways</i>	1.4*** (1.3 - 1.5)	0.9 ^{ns} (0.8 - 1.1)	2.3*** (1.8 - 2.9)	1.2 ^{ns} (1.0 - 1.5)
<i>LPSBiosynthesisPathways</i>	1.2** (1.1 - 1.3)	1.3** (1.1 - 1.5)	0.9 ^{ns} (0.7 - 1.1)	1.1 ^{ns} (0.9 - 1.4)
<i>MethanogenesisPathways</i>	1.2*** (1.1 - 1.4)	1.6*** (1.4 - 2.0)	1.2 ^{ns} (1.0 - 1.5)	1.3* (1.0 - 1.5)
<i>OxalateMetabolismPathways</i>	1.3*** (1.2 - 1.4)	0.9 ^{ns} (0.7 - 1.0)	2.1*** (1.6 - 2.6)	1.2* (1.0 - 1.5)
<i>SulfideProductionPathways</i>	1.1 ^{ns} (1.0 - 1.2)	0.7*** (0.6 - 0.9)	1.8*** (1.5 - 2.3)	1.1 ^{ns} (0.9 - 1.3)
<i>UricAcidProductionPathways</i>	1.5*** (1.4 - 1.6)	1.0 ^{ns} (0.8 - 1.1)	2.3*** (1.8 - 2.9)	1.3* (1.1 - 1.6)


Supplementary Table 3. Odds Ratio and Confidence Intervals shown in Figure 4. IBS cases are the composite of any IBS subtype classification, and cases for each IBS subtype classification are defined by the Rome IV Diagnostic Questionnaire. “Control” definitions are score-specific (Supplementary Table 1). Values represent Odds Ratios. Significance levels of the p-values are shown in superscript, with 95% Confidence Interval in parentheses. $p \leq 0.05$ (*); $p \leq 0.01$ (**); $p \leq 0.001$ (***); not significant (ns).

Score Name	IBS (max $n = 8,629$)	IBS-C (max $n = 1,942$)	IBS-D (max $n = 2,952$)	IBS-M (max $n = 3,309$)
<i>ButyrateProductionPathways</i>	1.5*** (1.3 - 1.6)	0.7*** (0.6 - 0.8)	2.7*** (2.4 - 3.1)	1.3*** (1.1 - 1.4)
<i>GABAProductionPathways</i>	1.8*** (1.6 - 1.9)	2.5*** (2.1 - 3.0)	1.6*** (1.4 - 1.8)	1.8*** (1.6 - 2.1)
<i>LacticAcidProductionPathways</i>	1.4*** (1.3 - 1.5)	0.8** (0.7 - 0.9)	2.2*** (2.0 - 2.5)	1.3*** (1.2 - 1.5)
<i>LPSBiosynthesisPathways</i>	1.1* (1.0 - 1.2)	1.3** (1.1 - 1.6)	1.0 ^{ns} (0.9 - 1.1)	1.1 ^{ns} (0.9 - 1.2)
<i>MethanogenesisPathways</i>	1.2*** (1.1 - 1.3)	1.8*** (1.5 - 2.1)	1.0 ^{ns} (0.9 - 1.1)	1.3*** (1.2 - 1.5)
<i>OxalateMetabolismPathways</i>	1.3*** (1.2 - 1.5)	0.7*** (0.6 - 0.8)	2.1*** (1.8 - 2.4)	1.2** (1.1 - 1.4)
<i>SulfideProductionPathways</i>	1.1** (1.0 - 1.2)	0.6*** (0.5 - 0.7)	1.7*** (1.5 - 1.9)	1.1 ^{ns} (0.9 - 1.2)
<i>UricAcidProductionPathways</i>	1.5*** (1.4 - 1.6)	0.9 ^{ns} (0.8 - 1.0)	2.3*** (2.0 - 2.7)	1.4*** (1.3 - 1.6)


Supplementary Figure 1. Landscape of score distribution. The distribution of eight functional pathway scores (A-H) in an independent cohort ($n = 71,220$ samples). The distribution of each pathway score across the entire cohort is expected to follow a Gaussian normal distribution, where a high score is “Good”. Some scores deviate significantly from this normal distribution, which can be attributed to missing molecular signatures in the reference cohort, resulting in extremely high or low scores. Scores exceeding 100 or falling below 0 were clipped.




Supplementary Figure 2. Genera of significantly increased species (differentially expressed) between self-reported IBS phenotypes and individuals with no comorbidities. Controls are defined as individuals with zero self-reported comorbidities. At the highest level, cases and controls were matched 1:5 for “IBS-C” (green; $n = 1,198$), “IBS-D” (blue; $n = 736$), and “IBS-M” (red; $n = 699$). All significantly increased species ($p \leq 0.05$ and $\log$ “Fold Change” ≥ 0.6) were combined into respective genera before constructing the Venn Diagram. All genera with differential expression consistent to Rome IV-determined IBS phenotypes (Supplementary Figure 4) are indicated with an asterisk (*).



Supplementary Figure 3. Genera of significantly decreased species (differentially expressed) between self-reported IBS phenotypes and individuals with no comorbidities. Controls are defined as individuals with zero self-reported comorbidities. At the highest level, cases and controls were matched 1:5 for “IBS-C” (green; $n = 1,198$), “IBS-D” (blue; $n = 736$), and “IBS-M” (red; $n = 699$). All significantly decreased species ($p \leq 0.05$ and $\log$ “Fold Change” ≤ -0.6) were combined into respective genera before constructing the Venn Diagram. All genera with differential expression consistent to Rome IV-determined IBS phenotypes (Supplementary Figure 5) are indicated with an asterisk (*).



Supplementary Figure 4. Genera of significantly increased species (differentially expressed) between Rome IV-defined IBS phenotypes and individuals with no comorbidities. Controls are defined as individuals with zero self-reported comorbidities. At the highest level, cases and controls were matched 1:5 for “IBS-C” (green; $n = 1,198$), “IBS-D” (blue; $n = 736$), and “IBS-M” (red; $n = 699$). All significantly increased species ($p \leq 0.05$ and $\log$ “Fold Change” ≥ 0.6) were combined into respective genera before constructing the Venn Diagram. All genera with differential expression consistent to self-reported IBS phenotypes (Supplementary Figure 2) are indicated with an asterisk (*).



Supplementary References.

- Ex1. Brown GC, Camacho M, Williams-Gray CH. The Endotoxin Hypothesis of Parkinson's Disease. *Mov Disord.* 2023;38(7):1143–55.
- Ex2. Xue H, Zhang M, Ma J, Chen T, Wang F, Tang X. Lactose-Induced Chronic Diarrhea Results From Abnormal Luminal Microbial Fermentation and Disorder of Ion Transport in the Colon. *Front Physiol.* 2020;11:877.
- Ex3. Triantafyllou K, Chang C, Pimentel M. Methanogens, Methane and Gastrointestinal Motility. *J Neurogastroenterol Motil.* 2013;20(1):31–40.
- Ex4. Usuda H, Okamoto T, Wada K. Leaky Gut: Effect of Dietary Fiber and Fats on Microbiome and Intestinal Barrier. *Int J Mol Sci.* 2021;22(14):7613.
- Ex5. Xiong J, Chen X, Zhao Z, Liao Y, Zhou T, Xiang Q. A potential link between plasma short-chain fatty acids, TNF- α level and disease progression in non-alcoholic fatty liver disease: A retrospective study. *Exp Ther Med.* 2022;24(3):598.
- Ex6. Jin M, Kalainy S, Baskota N, Chiang D, Deehan EC, McDougall C, et al. Faecal microbiota from patients with cirrhosis has a low capacity to ferment non-digestible carbohydrates into short-chain fatty acids. *Liver Int.* 2019;39(8):1437–47.
- Ex7. Flaig B, Garza R, Singh B, Hamamah S, Covasa M. Treatment of Dyslipidemia through Targeted Therapy of Gut Microbiota. *Nutrients.* 2023;15(1):228.
- Ex8. Xiao X, Hu X, Yao J, Cao W, Zou Z, Wang L, et al. The role of short-chain fatty acids in inflammatory skin diseases. *Front Microbiol.* 2023;13:1083432.
- Ex9. Eslick S, Williams EJ, Berthon BS, Wright T, Karihaloo C, Gately M, et al. Weight Loss and Short-Chain Fatty Acids Reduce Systemic Inflammation in Monocytes and Adipose Tissue Macrophages from Obese Subjects. *Nutrients.* 2022;14(4):765.
- Ex10. Kim HK, Rutten NBMM, Vaart IB van der, Niers LEM, Choi YH, Rijkers GT, et al. Probiotic supplementation influences faecal short chain fatty acids in infants at high risk for eczema. *Benef Microbes.* 2015;6(6):783–90.
- Ex11. Gio-Batta M, Sjöberg F, Jonsson K, Barman M, Lundell AC, Adlerberth I, et al. Fecal short chain fatty acids in children living on farms and a link between valeric acid and protection from eczema. *Sci Rep.* 2020;10(1):22449.
- Ex12. Gio-Batta M, Spetz K, Barman M, Bråbäck L, Norin E, Björkstén B, et al. Low Concentration of Fecal Valeric Acid at 1 Year of Age Is Linked with Eczema and Food Allergy at 13 Years of Age: Findings from a Swedish Birth Cohort. *Int Arch Allergy Immunol.* 2022;183(4):398–408.
- Ex13. Kanda N, Hoashi T, Saeki H. The Defect in Regulatory T Cells in Psoriasis and Therapeutic Approaches. *J Clin Med.* 2021;10(17):3880.
- Ex14. Reddel S, Chierico FD, Quagliariello A, Giancristoforo S, Vernocchi P, Russo A, et al. Gut microbiota profile in children affected by atopic dermatitis and evaluation of intestinal persistence of a probiotic mixture. *Sci Rep.* 2019;9(1):4996.
- Ex15. Nylund L, Nermes M, Isolauri E, Salminen S, Vos WM, Satokari R. Severity of atopic disease inversely correlates with intestinal microbiota diversity and butyrate-producing bacteria. *Allergy.* 2015;70(2):241–4.
- Ex16. Deng Y, Wang H, Zhou J, Mou Y, Wang G, Xiong X. Patients with Acne Vulgaris Have a Distinct Gut Microbiota in Comparison with Healthy Controls. *Acta Derm Venereol.* 2018;98(8):783–90.
- Ex17. Park HK, Lee SJ. Treatment of gouty arthritis is associated with restoring the gut microbiota and promoting the production of short-chain fatty acids. *Arthritis Res Ther.* 2022;24(1):51.
- Ex18. Jang YO, Kim OH, Kim SJ, Lee SH, Yun S, Lim SE, et al. High-fiber diets attenuate emphysema development via modulation of gut microbiota and metabolism. *Sci Rep.* 2021;11(1):7008.
- Ex19. Wu Y, Xu H, Tu X, Gao Z. The Role of Short-Chain Fatty Acids of Gut Microbiota Origin in Hypertension. *Front Microbiol.* 2021;12:730809.
- Ex20. Groot PF de, Belzer C, Aydin Ö, Levin E, Levels JH, Aalvink S, et al. Distinct fecal and oral microbiota composition in human type 1 diabetes, an observational study. *PLoS ONE.* 2017;12(12):e0188475.
- Ex21. Vatanen T, Franzosa EA, Schwager R, Tripathi S, Arthur TD, Vehik K, et al. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. *Nature [Internet].* 2018 Oct 1;562(7728):589–94. Available from: <https://doi.org/10.1038/s41586-018-0620-2>
- Ex22. Huang J, Pearson JA, Peng J, Hu Y, Sha S, Xing Y, et al. Gut microbial metabolites alter IgA immunity in type 1 diabetes. *JCI Insight.* 2020;5(10).
- Ex23. Skonieczna-Żydecka K, Grochans E, Maciejewska D, Szkup M, Schneider-Matyka D, Jurczak A, et al. Faecal Short Chain Fatty Acids Profile is Changed in Polish Depressive Women. *Nutrients.* 2018;10(12):1939.
- Ex24. Zheng P, Zeng B, Zhou C, Liu M, Fang Z, Xu X, et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism. *Mol Psychiatry.* 2016;21(6):786–96.

- Ex25. Lucas S, Omata Y, Hofmann J, Böttcher M, Iljazovic A, Sarter K, et al. Short-chain fatty acids regulate systemic bone mass and protect from pathological bone loss. *Nat Commun* [Internet]. 2018 Jan 4;9(1):55. Available from: <https://doi.org/10.1038/s41467-017-02490-4>
- Ex26. Vitetta L, Coulson S, Linnane AW, Butt H. The Gastrointestinal Microbiome and Musculoskeletal Diseases: A Beneficial Role for Probiotics and Prebiotics. *Pathogens*. 2013;2(4):606–26.
- Ex27. Olejniczak-Staruch I, Ciałżyńska M, Sobolewska-Sztychny D, Narbutt J, Skibińska M, Lesiak A. Alterations of the Skin and Gut Microbiome in Psoriasis and Psoriatic Arthritis. *Int J Mol Sci*. 2021;22(8):3998.
- Ex28. Sencio V, Gallerand A, Machado MG, Deruyter L, Heumel S, Soulard D, et al. Influenza Virus Infection Impairs the Gut's Barrier Properties and Favors Secondary Enteric Bacterial Infection through Reduced Production of Short-Chain Fatty Acids. *Infect Immun*. 2021;89(9):e00734-20.
- Ex29. Mueller NT, Differding MK, Zhang M, Maruthur NM, Juraschek SP, Miller ER, et al. Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial. *Diabetes Care*. 2021;44(7):1462–71.
- Ex30. Yang T, Richards EM, Pepine CJ, Raizada MK. The gut microbiota and the brain–gut–kidney axis in hypertension and chronic kidney disease. *Nat Rev Nephrol* [Internet]. 2018 Jul 1;14(7):442–56. Available from: <http://www.nature.com/articles/s41581-018-0018-2>
- Ex31. Aggarwal S, Ahuja V, Paul J. Attenuated GABAergic Signaling in Intestinal Epithelium Contributes to Pathogenesis of Ulcerative Colitis. *Dig Dis Sci*. 2017;62(10):2768–79.
- Ex32. Aggarwal S, Ahuja V, Paul J. Dysregulation of GABAergic Signalling Contributes in the Pathogenesis of Diarrhea-predominant Irritable Bowel Syndrome. *J Neurogastroenterol Motil*. 2018;24(3):422–30.
- Ex33. Bhat R, Axtell R, Mitra A, Miranda M, Lock C, Tsien RW, et al. Inhibitory role for GABA in autoimmune inflammation. *Proc Natl Acad Sci*. 2010;107(6):2580–5.
- Ex34. Kang DW, Ilhan ZE, Isern NG, Hoyt DW, Howsmon DP, Shaffer M, et al. Differences in fecal microbial metabolites and microbiota of children with autism spectrum disorders. *Anaerobe* [Internet]. 2018 Feb 1;49:121–31. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1075996417302305>
- Ex35. Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, et al. Ingestion of *Lactobacillus* strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. *Proc National Acad Sci* [Internet]. 2011 Sep 20;108(38):16050–5. Available from: <http://www.pnas.org/cgi/doi/10.1073/pnas.1102999108>
- Ex36. Strandwitz P, Kim KH, Terekhova D, Liu JK, Sharma A, Levering J, et al. GABA-modulating bacteria of the human gut microbiota. *Nat Microbiol* [Internet]. 2018 Dec 10; Available from: <https://doi.org/10.1038/s41564-018-0307-3>
- Ex37. Yu L, Han X, Cen S, Duan H, Feng S, Xue Y, et al. Beneficial effect of GABA-rich fermented milk on insomnia involving regulation of gut microbiota. *Microbiol Res*. 2020;233:126409.
- Ex38. Patterson E, Ryan PM, Wiley N, Carafa I, Sherwin E, Moloney G, et al. Gamma-aminobutyric acid-producing lactobacilli positively affect metabolism and depressive-like behaviour in a mouse model of metabolic syndrome. *Sci Rep*. 2019;9(1):16323.
- Ex39. Olson CA, Vuong HE, Yano JM, Liang QY, Nusbaum DJ, Hsiao EY. The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet. *Cell* [Internet]. 2018 Jun 1;173(7):1728–1741.e13. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0092867418305208>
- Ex40. Cookson TA. Bacterial-Induced Blood Pressure Reduction: Mechanisms for the Treatment of Hypertension via the Gut. *Front Cardiovasc Med*. 2021;8:721393.
- Ex41. Kimura M, Hayakawa K, Sansawa H. Involvement of γ -Aminobutyric Acid (GABA) B Receptors in the Hypotensive Effect of Systemically Administered GABA in Spontaneously Hypertensive Rats. *Jpn J Pharmacol*. 2002;89(4):388–94.
- Ex42. Bajic SS, Djokic J, Dinic M, Veljovic K, Golic N, Mihajlovic S, et al. GABA-Producing Natural Dairy Isolate From Artisanal Zlata Cheese Attenuates Gut Inflammation and Strengthens Gut Epithelial Barrier in vitro. *Front Microbiol*. 2019;10:527.
- Ex43. Abdelazez A, Abdelmotaal H, Evivie SE, Melak S, Jia FF, Khoso MH, et al. Screening Potential Probiotic Characteristics of *Lactobacillus brevis* Strains In Vitro and Intervention Effect on Type I Diabetes In Vivo. *BioMed Res Int*. 2018;2018:7356173.
- Ex44. Khrais A, Ali H, Choi S, Ahmed A, Ahlawat S. D-Lactic Acidosis in Short Bowel Syndrome. *Cureus*. 2022;14(5):e25471.
- Ex45. Washington C, Carmichael J. Management of Ischemic Colitis. *Clin Colon Rectal Surg*. 2012;25(04):228–35.
- Ex46. Hove H, Nordgaard-Andersen I, Mortensen PB. Faecal DL-Lactate Concentration in 100 Gastrointestinal Patients. *Scand J Gastroenterol*. 1994;29(3):255–9.

- Ex47. Bjerrum JT, Wang Y, Hao F, Coskun M, Ludwig C, Günther U, et al. Metabonomics of human fecal extracts characterize ulcerative colitis, Crohn's disease and healthy individuals. *Metabolomics*. 2015;11(1):122–33.
- Ex48. Hove H, Holtug K, Jeppesen PB, Mortensen BP. Butyrate absorption and lactate secretion in ulcerative colitis. *Dis Colon Rectum*. 1995;38(5):519–25.
- Ex49. Hove H, Mortensen PB. Influence of intestinal inflammation (IBD) and small and large bowel length on fecal short-chain fatty acids and lactate. *Dig Dis Sci*. 1995;40(6):1372–80.
- Ex50. Montgomery RD, Frazer AC, Hood C, Goodhart JM, Holland MR, Schneider R. Studies of intestinal fermentation in ulcerative colitis. *Gut*. 1968;9(5):521.
- Ex51. Vernia P, Caprilli R, Latella G, Barbetti F, Magliocca FM, Cittadini M. Fecal Lactate and Ulcerative Colitis. *Gastroenterology*. 1988;95(6):1564–8.
- Ex52. Vernia P, Gnaedinger A, Hauck W, Breuer RI. Organic anions and the diarrhea of inflammatory bowel disease. *Dig Dis Sci*. 1988;33(11):1353–8.
- Ex53. Gillis CC, Hughes ER, Spiga L, Winter MG, Zhu W, Carvalho TF de, et al. Dysbiosis-Associated Change in Host Metabolism Generates Lactate to Support Salmonella Growth. *Cell Host Microbe*. 2018;23(1):54–64.e6.
- Ex54. Sheedy JR, Wettenhall REH, Scanlon D, Gooley PR, Lewis DP, McGregor N, et al. Increased d-lactic Acid intestinal bacteria in patients with chronic fatigue syndrome. *vivo (Athens, Greece)*. 2009;23(4):621–8.
- Ex55. Crawford SO, Hoogeveen RC, Brancati FL, Astor BC, Ballantyne CM, Schmidt MI, et al. Association of blood lactate with type 2 diabetes: the Atherosclerosis Risk in Communities Carotid MRI Study. *Int J Epidemiology*. 2010;39(6):1647–55.
- Ex56. Bouter K, Bakker G, Levin E, Hartstra A, Kootte R, Udayappan S, et al. Differential metabolic effects of oral butyrate treatment in lean versus metabolic syndrome subjects. *Clin Transl Gastroenterol*. 2018;9(5):155.
- Ex57. Piper DW, Kemp ML, Fenton BH, Croydon MJ, Clarke AD. Gastric juice lactic acidosis in the presence of gastric carcinoma. *Gastroenterology*. 1970;58(6):766–71.
- Ex58. Stevens BR, Goel R, Seungbum K, Richards EM, Holbert RC, Pepine CJ, et al. Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression. *Gut*. 2018;67(8):1555.
- Ex59. Bigatello LM, Broitman SA, Fattori L, Paoli MD, Pontello M, Bevilacqua G, et al. Endotoxemia, encephalopathy, and mortality in cirrhotic patients. *Am J Gastroenterol*. 1987;82(1):11–5.
- Ex60. Lin RS, Lee FY, Lee SD, Tsai YT, Lin HC, Rei-Hwa L, et al. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. *J Hepatol*. 1995;22(2):165–72.
- Ex61. Chen G, Shi F, Yin W, Guo Y, Liu A, Shuai J, et al. Gut microbiota dysbiosis: The potential mechanisms by which alcohol disrupts gut and brain functions. *Front Microbiol*. 2022;13:916765.
- Ex62. Mohammad S, Thiernemann C. Role of Metabolic Endotoxemia in Systemic Inflammation and Potential Interventions. *Front Immunol*. 2021;11:594150.
- Ex63. Ramendra R, Isnard S, Mehraj V, Chen J, Zhang Y, Finkelman M, et al. Circulating LPS and (1→3)- β -D-Glucan: A Folie à Deux Contributing to HIV-Associated Immune Activation. *Front Immunol*. 2019;10:465.
- Ex64. Tulkens J, Vergauwen G, Deun JV, Geurickx E, Dhondt B, Lippens L, et al. Increased levels of systemic LPS-positive bacterial extracellular vesicles in patients with intestinal barrier dysfunction. *Gut*. 2020;69(1):191.
- Ex65. Sieve I, Ricke-Hoch M, Kasten M, Battmer K, Stapel B, Falk CS, et al. A positive feedback loop between IL-1 β , LPS and NEU1 may promote atherosclerosis by enhancing a pro-inflammatory state in monocytes and macrophages. *Vasc Pharmacol*. 2018;103:16–28.
- Ex66. Jaw JE, Tsuruta M, Oh Y, Schipilow J, Hirano Y, Ngan DA, et al. Lung exposure to lipopolysaccharide causes atherosclerotic plaque destabilisation. *Eur Respir J*. 2016;48(1):205–15.
- Ex67. Yoshida N, Emoto T, Yamashita T, Watanabe H, Hayashi T, Tabata T, et al. *Bacteroides vulgatus* and *Bacteroides dorei* Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis. *Circulation*. 2018 Nov 27;138(22):2486–98.
- Ex68. Dong Y, Wang P, Yang X, Chen M, Li J. Potential of gut microbiota for lipopolysaccharide biosynthesis in European women with type 2 diabetes based on metagenome. *Front Cell Dev Biol*. 2022;10:1027413.
- Ex69. An L, Wirth U, Koch D, Schirren M, Drefs M, Koliogiannis D, et al. The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases. *J Gastrointest Surg*. 2022;26(3):671–83.
- Ex70. Violi F, Cammisotto V, Bartimoccia S, Pignatelli P, Carnevale R, Nocella C. Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease. *Nat Rev Cardiol*. 2023;20(1):24–37.

- Ex71. Maes M, Kubera M, Leunis JC. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. *Neuro Endocrinol Lett.* 2008;29(1):117–24.
- Ex71. Finegold SM, Dowd SE, Gontcharova V, Liu C, Henley KE, Wolcott RD, et al. Pyrosequencing study of fecal microflora of autistic and control children. *Anaerobe.* 2010;16(4):444–53.
- Ex73. Nadal I, Donant E, Ribes-Koninckx C, Calabuig M, Sanz Y. Imbalance in the composition of the duodenal microbiota of children with coeliac disease. *J Méd Microbiol.* 2007;56(12):1669–74.
- Ex74. Feehley T, Belda-Ferre P, Nagler CR. What's LPS Got to Do with It? A Role for Gut LPS Variants in Driving Autoimmune and Allergic Disease. *Cell Host Microbe.* 2016;19(5):572–4.
- Ex75. Huang Z, Kraus VB. Does lipopolysaccharide-mediated inflammation have a role in OA? *Nat Rev Rheumatol.* 2016;12(2):123–9.
- Ex76. Mehta NN, McGillicuddy FC, Anderson PD, Hinkle CC, Shah R, Pruscino L, et al. Experimental Endotoxemia Induces Adipose Inflammation and Insulin Resistance in Humans. *Diabetes.* 2010;59(1):172–81.
- Ex77. Brown GC. The endotoxin hypothesis of neurodegeneration. *J Neuroinflammation.* 2019;16(1):180.
- Ex78. Kim KA, Jeong JJ, Yoo SY, Kim DH. Gut microbiota lipopolysaccharide accelerates inflammation in mice. *BMC Microbiol.* 2016;16(1):9.
- Ex79. Xia L, Xu Z, Zhou X, Bergmann F, Grabe N, Büchler MW, et al. Impaired autophagy increases susceptibility to endotoxin-induced chronic pancreatitis. *Cell Death Dis.* 2020;11(10):889.
- Ex80. Ren Z, Jiang J, Xie H, Li A, Lu H, Xu S, et al. Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China. *Oncotarget.* 2017;8(56):95176–91.
- Ex81. Liu Q, Tian X, Maruyama D, Arjomandi M, Prakash A. Lung immune tone via gut-lung axis: gut-derived LPS and short-chain fatty acids' immunometabolic regulation of lung IL-1 β , FFAR2, and FFAR3 expression. *Am J Physiol-Lung Cell Mol Physiol.* 2021;321(1):L65–78.
- Ex82. Yuan X, Wang R, Han B, Sun C, Chen R, Wei H, et al. Functional and metabolic alterations of gut microbiota in children with new-onset type 1 diabetes. *Nat Commun.* 2022;13(1):6356.
- Ex83. Maes M, Mihaylova I, Leunis JC. Increased serum IgA and IgM against LPS of enterobacteria in chronic fatigue syndrome (CFS): Indication for the involvement of gram-negative enterobacteria in the etiology of CFS and for the presence of an increased gut–intestinal permeability. *J Affect Disord.* 2007;99(1–3):237–40.
- Ex84. Weaver GA, Krause JA, Miller TL, Wolin MJ. Incidence of methanogenic bacteria in a sigmoidoscopy population: an association of methanogenic bacteria and diverticulosis. *Gut.* 1986;27(6):698.
- Ex85. Lecours PB, Marsolais D, Cormier Y, Berberi M, Haché C, Bourdages R, et al. Increased Prevalence of *Methanospaera stadtmanae* in Inflammatory Bowel Diseases. *PLoS ONE.* 2014;9(2):e87734.
- Ex86. Gottlieb K, Wachter V, Sliman J, Pimentel M. Review article: inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders. *Aliment Pharmacol Ther.* 2016;43(2):197–212.
- Ex87. Chaudhary PP, Conway PL, Schlundt J. Methanogens in humans: potentially beneficial or harmful for health. *Appl Microbiol Biotechnol.* 2018;102(7):3095–104.
- Ex88. Mathur R, Chua KS, Mamelak M, Morales W, Barlow GM, Thomas R, et al. Metabolic effects of eradicating breath methane using antibiotics in prediabetic subjects with obesity. *Obesity.* 2016;24(3):576–82.
- Ex89. Mathur R, Amichai M, Chua KS, Mirocha J, Barlow GM, Pimentel M. Methane and Hydrogen Positivity on Breath Test Is Associated With Greater Body Mass Index and Body Fat. *J Clin Endocrinol Metab.* 2013;98(4):E698–702.
- Ex90. Basseri RJ, Basseri B, Pimentel M, Chong K, Youdim A, Low K, et al. Intestinal methane production in obese individuals is associated with a higher body mass index. *Gastroenterol Hepatol.* 2012;8(1):22–8.
- Ex91. Mathur R, Kim G, Morales W, Sung J, Rooks E, Pokkunuri V, et al. Intestinal *Methanobrevibacter smithii* but not total bacteria is related to diet-induced weight gain in rats. *Obesity.* 2013;21(4):748–54.
- Ex92. Cesario V, Rienzo TAD, Campanale M, D'angelo G, Barbaro F, Gigante G, et al. Methane intestinal production and poor metabolic control in type I diabetes complicated by autonomic neuropathy. *Minerva Endocrinol.* 2014;39(3):201–7.
- Ex93. Barlow GM, Yu A, Mathur R. Role of the Gut Microbiome in Obesity and Diabetes Mellitus. *Nutr Clin Pr.* 2015;30(6):787–97.
- Ex94. Pimentel M, Lin HC, Enayati P, Burg B van den, Lee HR, Chen JH, et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. *Am J Physiol-Gastrointest Liver Physiol.* 2006;290(6):G1089–95.

- Ex95. Zompo FD, Ojetti V, Feliciani D, Mangiola F, Petruzzello C, Tesori V, et al. *Helicobacter pylori* infection is associated with high methane production during lactulose breath test. *Eur Rev Méd Pharmacol Sci*. 2016;20(16):3452–6.
- Ex96. Miele L, Valenza V, Torre GL, Montalto M, Cammarota G, Ricci R, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. *Hepatology*. 2009;49(6):1877–87.
- Ex97. Ghoshal UC, Baba CS, Ghoshal U, Alexander G, Misra A, Saraswat VA, et al. Low-grade small intestinal bacterial overgrowth is common in patients with non-alcoholic steatohepatitis on quantitative jejunal aspirate culture. *Indian J Gastroenterol*. 2017;36(5):390–9.
- Ex98. Rodriguez DA, Ryan PM, Monjaraz EMT, Mayans JAR, Quigley EM. Small Intestinal Bacterial Overgrowth in Children: A State-Of-The-Art Review. *Front Pediatr*. 2019;7:363.
- Ex99. Leite G, Morales W, Weitsman S, Celly S, Parodi G, Mathur R, et al. The duodenal microbiome is altered in small intestinal bacterial overgrowth. *PLoS ONE*. 2020;15(7):e0234906.
- Ex100. Djemai K, Drancourt M, Alou MT. Bacteria and Methanogens in the Human Microbiome: a Review of Syntrophic Interactions. *Microb Ecol*. 2022;83(3):536–54.
- Ex101. Yazici C, Arslan DC, Abraham R, Cushing K, Keshavarzian A, Mutlu EA. Breath Methane Levels Are Increased Among Patients with Diverticulosis. *Dig Dis Sci*. 2016;61(9):2648–54.
- Ex102. Jang SI, Kim JH, Youn YH, Park H, Lee SI, Conklin JL. Relationship Between Intestinal Gas and the Development of Right Colonic Diverticula. *J Neurogastroenterol Motil*. 2010;16(4):418–23.
- Ex103. Patil DP, Dhotre DP, Chavan SG, Sultan A, Jain DS, Lanjekar VB, et al. Molecular analysis of gut microbiota in obesity among Indian individuals. *J Biosci*. 2012;37(4):647–57.
- Ex104. Mbakwa CA, Penders J, Savelkoul PH, Thijs C, Dagnelie PC, Mommers M, et al. Gut colonization with *methanobrevibacter smithii* is associated with childhood weight development. *Obesity*. 2015;23(12):2508–16.
- Ex105. Haines A, Dilawari J, Metz G, Blendis L, Wiggins H. Breath-methane in patients with cancer of the large bowel. *Lancet*. 1977;310(8036):481–3.
- Ex106. Peled Y. Methane Production and Colon Cancer. *Gastroenterology*. 1985;88(5):1294.
- Ex107. Scanlan PD, Shanahan F, Marchesi JR. Human methanogen diversity and incidence in healthy and diseased colonic groups using *mcrA* gene analysis. *BMC Microbiol*. 2008;8(1):79.
- Ex108. Ghavami SB, Rostami E, Sephay AA, Shahrokh S, Balaii H, Aghdaei HA, et al. Alterations of the human gut *Methanobrevibacter smithii* as a biomarker for inflammatory bowel diseases. *Microb Pathog*. 2018;117:285–9.
- Ex109. Hwang L, Low K, Khoshini R, Melmed G, Sahakian A, Makhani M, et al. Evaluating Breath Methane as a Diagnostic Test for Constipation-Predominant IBS. *Dig Dis Sci*. 2010;55(2):398–403.
- Ex110. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. *Am J Gastroenterol*. 2003;98(2):412–9.
- Ex111. Reddymasu SC, McCallum RW. Small Intestinal Bacterial Overgrowth in Gastroparesis. *J Clin Gastroenterol*. 2010;44(1):e8–13.
- Ex112. Jangi S, Gandhi R, Cox LM, Li N, Glehn F von, Yan R, et al. Alterations of the human gut microbiome in multiple sclerosis. *Nat Commun*. 2016;7(1):12015.
- Ex113. Qian Y, Yang X, Xu S, Wu C, Song Y, Qin N, et al. Alteration of the fecal microbiota in Chinese patients with Parkinson's disease. *Brain, Behav, Immun*. 2018;70:194–202.
- Ex114. Bedarf JR, Hildebrand F, Coelho LP, Sunagawa S, Bahram M, Goeser F, et al. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients. *Genome Med*. 2017;9(1):39.
- Ex115. Lim MY, You HJ, Yoon HS, Kwon B, Lee JY, Lee S, et al. The effect of heritability and host genetics on the gut microbiota and metabolic syndrome. *Gut*. 2017;66(6):1031.
- Ex116. Fiedorek SC, Pumphrey CL, Casteel HB. Breath Methane Production in Children With Constipation and Encopresis. *J Pediatr Gastroenterol Nutr*. 1990;10(4):473–7.
- Ex117. Armougom F, Henry M, Vialettes B, Raccach D, Raoult D. Monitoring Bacterial Community of Human Gut Microbiota Reveals an Increase in *Lactobacillus* in Obese Patients and Methanogens in Anorexic Patients. *PLoS ONE*. 2009;4(9):e7125.
- Ex118. Million M, Angelakis E, Maraninchi M, Henry M, Giorgi R, Valero R, et al. Correlation between body mass index and gut concentrations of *Lactobacillus reuteri*, *Bifidobacterium animalis*, *Methanobrevibacter smithii* and *Escherichia coli*. *Int J Obes*. 2013;37(11):1460–6.
- Ex119. Borgo F, Riva A, Benetti A, Casiraghi MC, Bertelli S, Garbossa S, et al. Microbiota in anorexia nervosa: The triangle between bacterial species, metabolites and psychological tests. *PLoS ONE*. 2017;12(6):e0179739.

- Ex120. Mack I, Cuntz U, Grämer C, Niedermaier S, Pohl C, Schwartz A, et al. Weight gain in anorexia nervosa does not ameliorate the faecal microbiota, branched chain fatty acid profiles and gastrointestinal complaints. *Sci Rep*. 2016;6(1):26752.
- Ex121. Prochazkova P, Roubalova R, Dvorak J, Kreislinger J, Hill M, Tlaskalova-Hogenova H, et al. The intestinal microbiota and metabolites in patients with anorexia nervosa. *Gut Microbes*. 2021;13(1):1902771.
- Ex122. Piqué JM, Pallarés M, Cusó E, Vilar-Bonet J, Gassull MA. Methane production and colon cancer. *Gastroenterology*. 1984;87(3):601–5.
- Ex123. Waikar SS, Srivastava A, Palsson R, Shafi T, Hsu CY, Sharma K, et al. Association of Urinary Oxalate Excretion With the Risk of Chronic Kidney Disease Progression. *JAMA Intern Med*. 2019;179(4):542–51.
- Ex124. Liu M, Koh H, Kurtz ZD, Battaglia T, PeBenito A, Li H, et al. Oxalobacter formigenes-associated host features and microbial community structures examined using the American Gut Project. *Microbiome*. 2017;5(1):108.
- Ex125. Katoh R, Kawaoi A, Muramatsu A, Hemmi A, Suzuki K. Birefringent (Calcium Oxalate) Crystals in Thyroid Diseases. *Am J Surg Pathol*. 1993;17(7):698–705.
- Ex126. Pusztaszeri M. Birefringent crystals in thyroid fine-needle aspiration cytology. *Diagn Cytopathol*. 2016;44(10):814–5.
- Ex127. Reid JD, Choi CH, Oldroyd NO. Calcium Oxalate Crystals in the Thyroid: Their Identification, Prevalence, Origin, and Possible Significance. *Am J Clin Pathol*. 1987;87(4):443–54.
- Ex128. Cury DB, Moss AC, Schor N. Nephrolithiasis in patients with inflammatory bowel disease in the community. *Int J Nephrol Renov Dis*. 2013;6:139–42.
- Ex129. Liu M, Devlin JC, Hu J, Volkova A, Battaglia TW, Ho M, et al. Microbial genetic and transcriptional contributions to oxalate degradation by the gut microbiota in health and disease. *eLife*. 2021;10:e63642.
- Ex130. Kharlamb V, Schelker J, Francois F, Jiang J, Holmes RP, Goldfarb DS. Oral Antibiotic Treatment of *Helicobacter pylori* Leads to Persistently Reduced Intestinal Colonization Rates with *Oxalobacter formigenes*. *J Endourol*. 2011;25(11):1781–5.
- Ex131. Mulay SR, Eberhard JN, Pfann V, Marschner JA, Darisipudi MN, Daniel C, et al. Oxalate-induced chronic kidney disease with its uremic and cardiovascular complications in C57BL/6 mice. *Am J Physiol-Ren Physiol*. 2016;310(8):F785–95.
- Ex132. Liu Y, Li S, Zeng Z, Wang J, Xie L, Li T, et al. Kidney Stones and Cardiovascular Risk: A Meta-analysis of Cohort Studies. *Am J Kidney Dis*. 2014;64(3):402–10.
- Ex133. Mirmiran P, Bahadoran Z, Azizi F. Dietary oxalate-calcium balance and the incidence of hypertension and chronic kidney disease: a prospective study among an Asian population. *Nutr Metab*. 2022;19(1):74.
- Ex134. Nazzari L, Puri S, Goldfarb DS. Enteric hyperoxaluria: an important cause of end-stage kidney disease. *Nephrol Dial Transplant*. 2016;31(3):375–82.
- Ex135. Singh SB, Lin HC. Hydrogen Sulfide in Physiology and Diseases of the Digestive Tract. *Microorg*. 2015;3(4):866–89.
- Ex136. Hertel J, Harms AC, Heinken A, Baldini F, Thinnies CC, Glaab E, et al. Integrated Analyses of Microbiome and Longitudinal Metabolome Data Reveal Microbial-Host Interactions on Sulfur Metabolism in Parkinson's Disease. *Cell Rep*. 2019;29(7):1767-1777.e8.
- Ex137. Teigen L, Mathai PP, Lopez S, Matson M, Elkin B, Kozysa D, et al. Differential hydrogen sulfide production by a human cohort in response to animal- and plant-based diet interventions. *Clin Nutr*. 2022;41(6):1153–62.
- Ex138. Blachier F, Andriamihaja M, Larraufie P, Ahn E, Lan A, Kim E. Production of hydrogen sulfide by the intestinal microbiota and epithelial cells and consequences for the colonic and rectal mucosa. *Am J Physiol-Gastrointest Liver Physiol*. 2021;320(2):G125–35.
- Ex139. Portolese AC, McMullen BN, Baker SK, See JRC, Yochum GS, Koltun WA, et al. The Microbiome of Complicated Diverticulitis: An Imbalance of Sulfur-Metabolizing Bacteria. *Dis Colon Rectum*. 2023;66(5):707–15.
- Ex140. Wang Y, Nguyen LH, Mehta RS, Song M, Huttenhower C, Chan AT. Association Between the Sulfur Microbial Diet and Risk of Colorectal Cancer. *JAMA Netw Open*. 2021;4(11):e2134308.
- Ex141. Loubinoux J, Bronowicki J, Pereira IAC, Mouguel J, Faou AE. Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases. *FEMS Microbiol Ecol*. 2002;40(2):107–12.
- Ex142. Worcester EM. Stones from bowel disease. *Endocrinol Metab Clin North Am*. 2002;31(4):979–99.
- Ex143. Coe FL, Parks JH, Asplin JR. The Pathogenesis and Treatment of Kidney Stones. *N Engl J Med*. 1992;327(16):1141–52.
- Ex144. Rock KL, Kataoka H, Lai JJ. Uric acid as a danger signal in gout and its comorbidities. *Nat Rev Rheumatol*. 2013;9(1):13–23.
- Ex145. Li CC, Chien TM, Wu WJ, Huang CN, Chou YH. Uric acid stones increase the risk of chronic kidney disease. *Urolithiasis*. 2018;46(6):543–7.

- Ex146. King C, Lanaspa MA, Jensen T, Tolan DR, Sánchez-Lozada LG, Johnson RJ. Uric Acid as a Cause of the Metabolic Syndrome. *Contrib Nephrol.* 2018;192:88–102.
- Ex147. Daudon M, Traxer O, Conort P, Lacour B, Jungers P. Type 2 Diabetes Increases the Risk for Uric Acid Stones. *J Am Soc Nephrol.* 2006;17(7):2026–33.
- Ex148. Cupisti A, Morelli E, Meola M, Cozza V, Parrucci M, Barsotti G. Hypertension in Kidney Stone Patients. *Nephron.* 1996;73(4):569–72.
- Ex149. Devarajan A. Cross-talk between renal lithogenesis and atherosclerosis: an unveiled link between kidney stone formation and cardiovascular diseases. *Clin Sci.* 2018;132(6):615–26.
- Ex150. Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH, et al. Relationship Between Serum Uric Acid Concentration and Insulin Resistance and Metabolic Syndrome. *Circ J.* 2005;69(8):928–33.
- Ex151. Carbone A, Salhi YA, Tasca A, Palleschi G, Fuschi A, Nunzio CD, et al. Obesity and kidney stone disease: a systematic review. *Minerva Urol e Nefrol.* 2018;70(4):393–400.